Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avidity Biosciences Inc (NQ: RNA )

42.56 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avidity Biosciences Inc

< Previous 1 2 3 4 5 6 Next >
Expert Ratings for Avidity Biosciences
Via Benzinga
Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock
Via Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
Peering Into Avidity Biosciences's Recent Short Interest
Avidity Biosciences's (NASDAQ:RNA) short percent of float has fallen 26.62% since its last report. The company recently reported that it has 6.51 million shares sold short, which is 11.33% of all... 
Via Benzinga
EXCLUSIVE: The Benzinga Moneymaker Series, 5 Emerging Stocks For Investors To Watch
Investors are on the hunt for undervalued, underfollowed and emerging stocks to spot opportunities. The rise of social media and retail traders gave way to countless methods to uncover new information.... 
Via Benzinga
Expert Ratings for Avidity Biosciences
Via Benzinga
Novavax, Tesla, Western Digital And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Tesla, Amazon, Novavax, Lennar Corp, Avidity Biosciences: Why These 5 Stocks Are Drawing Retail Investors' Attention Today
Major Wall Street indices closed in the red on Wednesday despite an anticipated 50 basis points hike by the Federal Reserve as Chair Jerome Powell indicated the need for more data before the central... 
Via Benzinga
Dow Drops Over 300 Points After Fed Raises Key Overnight Interest Rate By 50 bps
U.S. stocks turned lower toward the end of trading, after the Federal Reserve announced its policy decision. 
Via Benzinga
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
Business wins are shining the spotlight on these two companies. 
Via The Motley Fool
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
Avidity Biosciences (NASDAQ: RNA) Posts Positive Phase 1/2 MARINA Data on AOC 1001, Announcing the First Successful Delivery of RNA to Muscle
Avidity Biosciences, Inc. (NASDAQ: RNA) is engaged as a biopharmaceutical company, which is focused on developing a new class of 
Via Spotlight Growth
How A First-Ever In Gene Silencing Catapulted Avidity Biosciences Into The Stratosphere
The company tested its efforts in myotonic dystrophy 1, a form of muscular dystrophy. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Avidity Biosciences Shares Gain On Encouraging Data From Early-Stage Myotonic Dystrophy Trial
Via Benzinga
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
What's Going On With Avidity Biosciences Stock?
Avidity Biosciences Inc (NASDAQ: RNA) shares are trading higher Wednesday after the company announced positive data demonstrating the first-ever successful 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
AiViva's Diverse Product Pipeline Could Have The Potential To Transform Unmet Medical Needs
AiViva BioPharma is a clinical-stage biotech company developing innovative and transformative treatments and products to address unmet medical needs for a wide array of diseases.  
Via Benzinga
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Wednesday, 10/19, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
Nasdaq Turns Higher; Crude Oil Rises Over 2%
U.S. stocks pared some losses toward the end of trading, with the Nasdaq Composite turning higher on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Avidity Biosciences, Kronos Worldwide And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 180 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
US Stocks Turn Lower; Dow Dips 175 Points
U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 175 points on Tuesday. 
Via Benzinga
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
US Stocks Open Higher; Dow Surges 300 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 300 points on Tuesday. 
Via Benzinga
Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study
The stock has a high IBD Digital rating, but plummeted on the news. 
Via Investor's Business Daily
FDA Slaps Clinical Hold On Avidity's Early-Stage Myotonic Dystrophy Trial
The FDA has placed a partial clinical hold on new participant enrollment in Avidity Biosciences Inc's (NASDAQ: RNA) Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.